Tri-GalNAc(OAc)3 (TFA)

SKU HY-148118A-10 mg Category Tags , ,

$220$350

Products Details

Product Description

– Tri-GalNAc(OAc)3 TFA is a tri-GalNAc ligand that can be used for the synthesis of GalNAc-LYTAC. GalNAc-LYTAC engages the asialoglycoprotein receptor for targeted protein degradation. tri-GalNAc: triantenerrary N-acetylgalactosamine; LYTAC: lysosome-targeting chimera[1].

Web ID

– HY-148118A

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture and light)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C81H129F3N10O38

References

– [1]Ahn G, et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat Chem Biol. 2021 Sep;17(9):937-946.

CAS Number

– 1159408-65-7

Molecular Weight

– 1907.93

Compound Purity

– 98.0

SMILES

– CC(O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1OC(C)=O)COC(C)=O)OCCCCC(NCCCNC(CCOCC(COCCC(NCCCNC(CCCCO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)COC(C)=O)OC(C)=O)OC(C)=O)NC(C)=O)=O)=O)(N)COCCC(NCCCNC(CCCCO[C@H]3[C@@H]([C@H]([C@H]([C@H](O3)COC(C)=O)OC(C)=O)OC(C)=O)NC(C)=O)=O)=O)=O)=O)NC(C)=O)=O.OC(C(F)(F)F)=O

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– 10 mM in DMSO

Target

– LYTACs

Pathway

– PROTAC

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=